OXYFEDRINE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H23NO3
Molecular Weight	313.3908
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

COC1=CC=CC(=C1)C(=O)CCN[C@@H](C)[C@H](O)C2=CC=CC=C2

InChI

InChIKey=GDYUVHBMFVMBAF-LIRRHRJNSA-N

InChI=1S/C19H23NO3/c1-14(19(22)15-7-4-3-5-8-15)20-12-11-18(21)16-9-6-10-17(13-16)23-2/h3-10,13-14,19-20,22H,11-12H2,1-2H3/t14-,19-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C19H23NO3
Molecular Weight	313.3908
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

Oxyfedrine, an amino ketone derivative and partial agonist at beta receptors, has been shown to have potent antianginal properties and to increase coronary blood flow in normal and ischemic myocardial regions.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 87	Partial Agonist 290

Conditions

Condition	Modality	Targets	Highest Phase	Product
Angina pectoris 106	Primary		Approved 8,429	Ildamen
Myocardial infarction 121	Primary		Approved 8,429	Oxyfedrine

Doses

Show entries

Dose	Population	Adverse events
32 mg 3 times / day multiple, oral Higher than recommended	unhealthy, ADULT	Disc. AE: Nausea, Vomiting...
24 mg 3 times / day multiple, oral Recommended	unhealthy, ADULT	Disc. AE: Taste loss, Myocardial infarction...

Showing 1 to 2 of 2 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Nausea	3.3% Disc. AE	32 mg 3 times / day multiple, oral Higher than recommended	unhealthy, ADULT
Vomiting	3.3% Disc. AE	32 mg 3 times / day multiple, oral Higher than recommended	unhealthy, ADULT
Myocardial infarction	4.3% Disc. AE	24 mg 3 times / day multiple, oral Recommended	unhealthy, ADULT
Taste loss	4.3% Disc. AE	24 mg 3 times / day multiple, oral Recommended	unhealthy, ADULT

Showing 1 to 4 of 4 entries

Previous1Next

PubMed

Title	Date	PubMed
No data available in table

Patents

Sample Use Guides

In Vivo Use Guide

Oral Myocardial infarction, Angina pectoris Adult: 8-24 mg tid.

Route of Administration: Oral

In Vitro Use Guide

Oxyfedrine was tested in vitro against 471 strains of bacteria from two Gram positive and fourteen Gram negative genera. The minimum inhibitory concentration (MIC) of oxyfedrine was determined by agar dilution method, which ranged from 50-200 ug/ml in most of the strains, while some strains were inhibited at even lower concentrations.